Table 5 Influencing factors of abnormal liver function in the Omicron BA5.2 and prototype patients

N

77

26

Gender

2.620

0.106

 male

49 (63.6%)

21 (84.0%)

 female

28 (26.4%)

5 (16.0%)

Age (years)

54.8 ± 16.64

53.0 ± 13.42

0.499

0.619

Vaccination History

0 (0.0%)

26 (100.0%)

103.000

< 0.001

Type of the novel coronavirus

20.740

< 0.001

 Mild/Common

44 (57.1%)

26 (100.0%)

 Severe/Critical

43 (42.9%)

0 (0.0%)

Complications

26 (33.8%)

14 (18.2%)

3.299

0.069

SpO₂ (%)

91.56 ± 13.70

97.62 ± 1.65

2.242

0.027

T (℃)

37.93 ± 0.85

37.49 ± 1.20

2.069

0.041

ALB(mg·L^-1 )

35.01 ± 4.71

42.11 ± 3.05

7.711

< 0.001

CRP(g·L^-1 )

40.00 ± 57.21

16.76 ± 22.56

3.127

0.001

D-dimer(mg·L^-1)

5.91 ± 10.22

0.40 ± 0.35

2.069

0.161

Therapeutic drugs

 Hormone

50 (64.9%)

0 (0.0%)

32.810

< 0.001

 Antibiotic

70 (90.9%)

3 (11.5%)

59.320

< 0.001

 Chinese patent medicine

62 (80.5%)

17 (65.4%)

2.491

0.115

Chloroquine

14 (18.2%)

0 (0.0%)

5.471

0.019